Director, Global Market Access Strategy – Oncology (Remote)
Illumina- Full Time
- Expert & Leadership (9+ years)
Orca Bio is a late-stage biotechnology company redefining the transplant process by developing next-generation cell therapies with the goal of providing significantly better survival rates with dramatically fewer risks. With their purified, high-precision investigational cell therapies, Orca Bio aims to not only replace patients' blood and immune systems with healthy ones but also restore their lives.
The Site Onboarding & Market Enablement Lead will be responsible for driving the execution of Orca Bio’s treatment center onboarding, activation, and ongoing site engagement to ensure operational readiness for ORCA-T administration. This role will develop and implement scalable models and processes for site onboarding, treatment center certification, and institutional support to enable a smooth launch and sustained adoption of the therapy. This position will work cross-functionally with teams across commercial, operational, and clinical functions and will manage a growing team as the program scales.
Note: Travel ~ 30%
Treatment Center Onboarding, Activation & Operational Readiness
Institutional Engagement & Enablement Strategy
Cross-Functional Collaboration
Team Leadership & Development
Develops and commercializes cell therapies
Orca Bio operates in the biotechnology sector, specifically focusing on cell therapies that utilize the body's own cells to treat diseases. The company works to enhance these therapies, aiming to make them safer and more effective for patients. Orca Bio's products are primarily used by healthcare providers who administer these therapies to patients as part of their treatment plans. Unlike many competitors, Orca Bio emphasizes a strong team culture and values communication with stakeholders, keeping them informed about the company's progress and developments. The goal of Orca Bio is to improve patient outcomes through advanced cell therapies, addressing conditions that currently have limited treatment options.